Skip to main content
. 2012 Jun 22;7(6):e38929. doi: 10.1371/journal.pone.0038929

Table 2. Cross-strain influenza A(H3N2) antibody responses measured by HI assay.* .

GROUP Yam/Vic: 2008–09/2010–11 TIV Sequence Initiating antigen Boosting antigen
Test Antigen Brisbane-like Brisbane-like Perth Perth
Brisbane-like Pre- vaccination Post 2008–09 TIV 1a Post 2008–09 TIV 2b Post 2010–11 TIV 1a Post 2010–11 TIV 2a
GMT (95%CI) 5.0 32.5 (25.6–41.3) 130 (102.3–165.1) 1194.3 (729.4–1955.5) 1114.3 (667.7–1859.6)
GMTR 6.50 26.0 9.19 0.93
% titre ≥40 (95%CI) 0 70 (35–100) 100 100 100
Perth
GMT (95%CI) 5.0 5.0 6.2 (4.4–8.6) 557.2 (302.9–1024.9) 519.8 (324.8–832.1)
GMTR 1 1.24 89.87 0.93
% titre ≥40 (95%CI) 0 0 0 100 100
GROUP Vic/Yam: 2010–11/2008–09 TIV Sequence Initiating antigen Boosting antigen
Test antigen Perth Perth Brisbane-like Brisbane-like
Brisbane-like Pre- vaccination Post 2010–11 TIV 1 a Post 2010–11 TIV 2 b Post 2008–09 TIV 1 a Post 2008–09 TIV 2 a
GMT (95%CI) 5.0 5.0 6.2 (4.8–7.8) 343 (189.4–621) 452.5 (296.9–689.7)
GMTR 1.00 1.24 55.32 1.32
% titre ≥40 (95%CI) 0 0 0 100 100
Perth
GMT (95%CI) 5.0 11.5 (6.5–20.2) 183.8 (134.3–251.5) 787.9 (523.8–1185.2) 844.5 (597.1–1194.4)
GMTR 2.3 36.76 4.29 1.07
% titre ≥40 (95%CI) 0 20 (0 – 50) 100 100 100

HI = hemagglutination inhibition; TIV  =  trivalent inactivated influenza vaccine. Note that undetectable titres <10 were assigned a value of 5.

*

Unit of analysis pooled sera from 5 mice, thus 10 pools from 50 mice were available for this experiment.

a

Measured two weeks after specified TIV dose;

b

Measured two months after specified TIV dose.

Compared to pre-immunization for priming antigens; compared to immediately preceding titre for boosting antigens.

Brisbane-like  =  A/Uruguay/716/2007(NYMC 175C)(H3N2) considered antigenically equivalent to the WHO recommended A/Brisbane/10/2007(H3N2) component of the 2008–09 northern hemisphere TIV.

Perth  =  A/Perth/16/2009(H3N2)-like, component of the northern hemisphere 2010–11 TIV.